peptide research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== Project Texas === In response to security concerns of the United States government, TikTok has been working to silo privileged user data within the United States under oversight from the US government or a third party such as Oracle. Named Project Texas, the initiative focuses on unauthorized access, state influence, and software security. A new subsidiary, TikTok US Data Security Inc. (USDS), was created to manage user data, software code, back-end systems, and content moderation. It would report to the Committee on Foreign Investment in the United States (CFIUS), not ByteDance or TikTok, even for hiring practices. Oracle would review and spot check the data flows through USDS. It would also digitally sign software code, approve updates, and oversee content moderation and recommendation. Physical locations would be established so that Oracle and the US government could conduct their own reviews. The company has been engaged in confidential negotiations over the project with CFIUS since 2021 and submitted its proposal but received little response from the panel afterward. In March 2023, a former employee of the company said Project Texas did not go far enough and that a complete "re-engineering" would be needed. TikTok responded by saying that Project Texas already is a re-engineering of the app and that the former employee left in 2022 before the project specifications were finalized. Other former employees had their own takes on the situation. A data scientist said US user data were emailed to ByteDance workers in China to identify viewer interests.
=== Category:EC 1.3 (act on the CH-CH group of donors) === Category:EC 1.3.1 (with NAD+ or NADP+ as acceptor) Biliverdin reductase EC 1.3.1.24 Category:EC 1.3.2 (with a cytochrome as acceptor) Category:EC 1.3.3 (with oxygen as acceptor) Protoporphyrinogen oxidase EC 1.3.3.4 Category:EC 1.3.5 (with a quinone or similar compound as acceptor) Category:EC 1.3.7 (with an iron–sulfur protein as acceptor) Category:EC 1.3.99 (with other acceptors)
== Termination == Termination occurs when one of the three termination codons moves into the A site. These codons are not recognized by any tRNAs. Instead, they are recognized by proteins called release factors, namely RF1 (recognizing the UAA and UAG stop codons) or RF2 (recognizing the UAA and UGA stop codons). These factors trigger the hydrolysis of the ester bond in peptidyl-tRNA and the release of the newly synthesized protein from the ribosome. A third release factor RF-3 catalyzes the release of RF-1 and RF-2 at the end of the termination process.
== Criticisms and controversies == In 1997, Dunkindonuts.org was established by a customer for disgruntled consumers and employees to lodge complaints about the company. The site appeared ahead of the company's own website in many search engines and received national media coverage before being purchased by Dunkin' Donuts in 1999. Dunkin' Donuts was criticized by one of its franchisees for allegedly forcing single-store owners to agree to a buyout at a loss for minor infractions. Dunkin' Donuts sued franchise owners 154 times from 2006 to April 2008. Over the same time span, McDonald's was involved in five lawsuits. Subway, a company that has four times the number of locations as Dunkin' Donuts, sued its franchisees 12 times. These figures do not include arbitrations, which the companies use in pursuing legal claims against their franchisees. Franchisees allege that the company's business strategy needs mainly multi-unit franchisees. In May 2010, Dunkin' Donuts was criticized for advertising "Free Iced Coffee Day" on its national Facebook page, which took place in only 13 cities. Due to the limited scope of the promotion, many customers became dissatisfied with the lack of free iced coffee and vented their anger on the Dunkin' Donuts Facebook page. In 2012, Dunkin' Donuts published its first formal Animal Welfare Policy, outlining its approach to humane sourcing and supplier standards. The company committed to eliminating gestation crates from its U.S.
In 1990, the country had a Human Development Index of 0.920, placing it in the 'high' category of human development. It was the third-highest in the Eastern Bloc, behind Czechoslovakia and East Germany, and the 25th in the world of 130 countries.
Sources: en.wikipedia.org
Harriet Jane Lawrence (September 13, 1883 – February 28, 1974) was an American physician and pathologist who was among the early women to specialize in laboratory medicine in the United States and the first known woman pathologist in Oregon. She earned her medical degree from Boston University School of Medicine in 1912 and established a clinical laboratory in Portland the following year, directing it for more than fifty years. During the 1918 influenza pandemic, Lawrence isolated hemolytic streptococcus from infected patients and developed a bacterial vaccine intended to combat secondary pneumonia associated with influenza. Although the viral cause of influenza was not yet understood, her work contributed to statewide treatment efforts and brought her national recognition. Over the course of her career, she supported the early medical career of Alan L. Hart and advocated for expanded opportunities for women in medicine.
A linear series of three quadrupoles is known as a triple quadrupole mass spectrometer. The first (Q1) and third (Q3) quadrupoles act as mass filters, and the middle (q2) quadrupole is employed as a collision cell. This collision cell is an RF-only quadrupole (non-mass filtering) using Ar, He, or N2 gas (~10−3 Torr, ~30 eV) for collision induced dissociation of selected parent ion(s) from Q1. Subsequent fragments are passed through to Q3 where they may be filtered or fully scanned. This process allows for the study of fragments that are useful in structural elucidation by tandem mass spectrometry. For example, the Q1 may be set to 'filter' for a drug ion of known mass, which is fragmented in q2. The third quadrupole (Q3) can then be set to scan the entire m/z range, giving information on the intensities of the fragments. Thus, the structure of the original ion can be deduced. The arrangement of three quadrupoles was first developed by Jim Morrison of La Trobe University in Australia for the purpose of studying the photodissociation of gas-phase ions. The first triple-quadrupole mass spectrometer was developed at Michigan State University by Christie Enke and graduate student Richard Yost in the late 1970s. Quadrupoles can be used in hybrid mass spectrometers. For example, a sector instrument can be combined with a collision quadrupole and quadrupole mass analyzer to form a hybrid instrument.
=== Pharmacodynamics === Pinoline shows affinity for serotonin receptors, including the serotonin 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors (Ki = 156–4,335 nM). It is a high-efficacy partial agonist of the serotonin 5-HT2A receptor, an antagonist of the serotonin 5-HT2B receptor, and a full agonist of the serotonin 5-HT2C receptor, with EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values of 2,140 nM (75%) at the serotonin 5-HT2A receptor and 33 nM (95%) at the serotonin 5-HT2C receptor and an IC50Tooltip half-maximal inhibitory concentration of 1,120 nM at the serotonin 5-HT2B receptor. Hence, pinoline appears to act as a potent and selective serotonin 5-HT2C receptor agonist. The drug shows affinity for the serotonin transporter (SERT) (Ki = 172–572 nM). It is a serotonin reuptake inhibitor, with an IC50 value of 1,100 nM. Pinoline shows affinity for the imidazoline I2 receptor (Ki = 1,640 nM) and for the α2-adrenergic receptor (Ki = 7,830 nM). Conversely, it shows no affinity for the dopamine D2 receptor (Ki = >10,000 nM). The drug is a weak monoamine oxidase inhibitor (MAOI), with an IC50 value for inhibition of MAO-ATooltip monoamine oxidase A of 41,500 nM. Both pinoline and tryptoline partially substitute for the psychedelic drug LSD in rodent drug discrimination tests. The substitution by tryptoline was further assessed and was found to be blocked by the serotonin receptor antagonist pizotifen and by the serotonin synthesis inhibitor para-chlorophenylalanine (PCPA).
Naturally occurring titanium (22Ti) is composed of five stable isotopes; 46Ti, 47Ti, 48Ti, 49Ti and 50Ti with 48Ti being the most abundant (73.8% natural abundance). Twenty-three radioisotopes have been characterized, with the most stable being 44Ti with a half-life of 59.1 years and 45Ti with a half-life of 184.8 minutes. All of the remaining radioactive isotopes have half-lives that are less than 10 minutes, and the majority of these have half-lives that are less than one second. The isotopes of titanium range from 39Ti to 66Ti. The primary decay mode for isotopes lighter than the stable isotopes is β+ and the primary mode for the heavier ones is β−; the decay products are respectively scandium isotopes and vanadium isotopes. There are two stable isotopes of titanium with an odd number of nucleons, 47Ti and 49Ti, which thus have non-zero nuclear spin of 5/2− and 7/2− (respectively) and are NMR-active.
Doppler ultrasound is less useful as it provides little information about the part of the artery close to the skull base and in the vertebral foramina, and any abnormality detected on ultrasound would still require confirmation with CT or MRI.
Sources: en.wikipedia.org
Withdrawal symptoms include headaches, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating, dysphoria, dizziness, derealization, depersonalization, numbness/tingling of extremities, hypersensitivity to light, sound, and smell, perceptual distortions, nausea, vomiting, diarrhea, appetite loss, hallucinations, delirium, seizures, tremor, stomach cramps, myalgia, agitation, palpitations, tachycardia, panic attacks, short-term memory loss, and hyperthermia. It takes about 18–36 hours for lorazepam to be removed from the body.
==== Urquía Carreño resigns ==== On August 18, 2024, a special session of more than a hundred Freemasons was called by Urquía Carreño to gather at the theatre hall of the Grand Lodge of Cuba, on the 3rd floor of the building. One Cuban Freemason told reporters that: "...he had manipulated a circus to stay in office. He's shameless, they were lies after lies; all the brothers were standing asking him to hand over the keys to his office." The people in the theatre started chanting: "Hand over and leave!" After tensions had escalated, Urquía Carreño left the theatre to go back to his office. However, the Freemasons followed him up to the eleventh floor. Urquía Carreño agreed to meet with representatives of the delegation in his office, so three men were chosen to represent them. The three men sat with three of Urquía Carreño's men, and discussed terms of negotiation, while the rest of the delegation waited in the hallway. On August 18, 2024, after two hours of negotiation, Urquía Carreño finally relented and agreed to tender his resignation. In his resignation, he said that it was: "for the good of the institution." Mayker Filema Duarte assumed the role of Acting Grand Master until an election could be held, and immediately launched a financial audit of the entire Grand Lodge. At the beginning of September, Filema Duarte accused Urquía Carreño of the theft of yet another $MN2,116,555.33, stolen sometime between January and August 2024.
It also requires secondary dressing because wounds can quickly dry up with alginate dressing. Hydrofiber dressing: Made up of sodium carboxymethyl cellulose, hydrofibers can absorb high amounts of wound discharge, forming a gel and preventing skin maceration.
=== Function in pregnancy === Progesterone plays a crucial role in pregnancy by supporting fetal development and maintaining the pregnancy. It is involved in the menstrual cycle, implantation, and is required for pregnancy maintenance. During implantation, it plays a role in its preservation through modulating the maternal immune response and suppressing the inflammatory response. By decreasing the maternal immune response, progesterone can allow the pregnancy to be accepted. Progesterone prepares the endometrium for implantation, as the level of progesterone increases, the capillaries grow. These capillaries spread throughout the granulosa layer of cells which promotes vascularization and blood flow in the endometrium, ensuring an adequate blood supply to the developing placenta and fetus. On the other hand, when there is no pregnancy occurred, the level of progesterone will decrease, which leads to menstruation. This means that bleeding from women's menstruation is bleeding after progesterone withdrawal.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.